25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
May 2024 in “Asian Journal of Medical Sciences” Skin changes like dryness and hair loss can signal hypothyroidism before tests confirm it.
November 2013 in “Institutional Repositories DataBase (IRDB)” Gamma-ray exposure during hair rest phase harms hair growth and color in mice.
37 citations
,
May 2018 in “Transgender health” Oral estradiol works for many transgender women but needs personalized dosing and monitoring.
1 citations
,
July 2015 in “AACE clinical case reports” Removing both ovaries treated the woman's excess male hormone symptoms.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
September 2023 in “Minia Journal of Medical Research” Intralesional vitamin D3 is a safe, effective treatment for patchy alopecia areata.
November 2022 in “The Indian journal of chest diseases & allied sciences” Isoniazid can rarely cause hair loss, which is reversible after stopping the drug.
July 2025 in “Journal of Investigative Dermatology”
8 citations
,
September 2018 in “Journal of Cosmetic Dermatology” Lower irisin levels in the blood may indicate more severe acne.
December 2018 in “Dermatologic Surgery” September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
32 citations
,
March 2021 in “Journal of endocrinological investigation” Thyroid hormones are important for skin health and changes in them can affect conditions like hair loss and eczema.
9 citations
,
October 1982 in “PubMed”
3 citations
,
October 2003 in “Annals of Oncology” A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.
8 citations
,
March 2012 in “Mass spectrometry letters” The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.
October 2024 in “Journal of the Endocrine Society” A rare ovarian tumor caused high testosterone in a postmenopausal woman, resolved by surgery.
October 2009 in “The American Journal of Gastroenterology” Excessive selenium intake can cause liver damage.
13 citations
,
October 2005 in “Analytical Sciences” A new method was developed to measure and assess the activity and inhibition of the enzyme steroid 5α-reductase.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
January 2026 in “Nature Communications” A wearable device using NIR light may help treat hair loss non-invasively.
4 citations
,
January 1991 in “Journal of obstetrics and gynaecology” The photographic method accurately measures hair growth and both treatments effectively reduced hair growth in hirsute women.
1 citations
,
January 1998 in “International journal of cancer” Rubbing vitamin D3 on skin can help prevent hair loss from chemotherapy and slow breast tumor growth in mice.
3 citations
,
January 1996 in “Journal of Dermatological Treatment” The ointment is a safe, effective, and well-tolerated treatment for certain types of psoriasis.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.